News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

Final result of PledPharma’s rights issue

December 2, 2016

PledPharma AB
Company Announcement

Final result of PledPharma’s rights issue

Stockholm, 2016-12-02 07:30 CET (GLOBE NEWSWIRE) -- 
The result of PledPharma AB’s (publ) (“PledPharma” or the “Company”) rights
issue, for which the subscription period ended on 29 November 2016, indicated
that 8,755,570 shares, representing approximately 43.2 percent of the offered
shares, were subscribed for by exercise of subscription rights. Additionally,
applications for subscription without subscription rights of 42,759 shares,
corresponding to approximately 0.2 percent of the offered shares, have been
received. The remaining 11,479,444 shares will be allotted to the guarantors
pro rata in relation to their total undertaking, in accordance with the
underwriting agreements entered into with the Company. Through the rights
issue, which consequently is fully subscribed, PledPharma will receive proceeds
amounting to approximately SEK 406 million before transaction related costs. 

Those who have subscribed for shares without subscription rights will be
allotted shares according to the principles outlined in the prospectus. Such
subscribers who have been allotted shares without subscription rights are
expected to be notified on 2 December 2016. Only those who are allotted shares
will be notified. 

Through the rights issue PledPharma’s share capital increases by approximately
SEK 1,067,252 from SEK 1,494,152 to SEK 2,561,404 and the total number of
shares increases by 20,277,773 from 28,388,883 to 48,666,656 when the rights
issue is registered by the Swedish Companies Registration Office. 

The final day for trading in paid subscribed shares (BTAs) was 1 December 2016.
The new shares subscribed for with subscription rights are expected to start
trading on Nasdaq Stockholm on 7 December 2016, and the shares subscribed for
without subscription rights on 15 December 2016. 

For further information, please contact:

Jacques Näsström, CEO, +46 73 713 09 79

Michaela Gertz, CFO, phone: +46 709 26 17 75

For more information about the Company, please visit

Stockholm, 2 December 2016
PledPharma AB (publ)

The information in this press release is such that PledPharma AB (publ) must
disclose in accordance with Market Abuse Act. The information was provided
through GlobeNewswire for publication on 2 December 2016 at 07.30 CET 


The information in this press release does not contain or constitute an
invitation or offer from PledPharma AB (publ) (”PledPharma”), Carnegie
Investment Bank AB (publ) or any other person to acquire, subscribe for or
otherwise trade in shares, subscription rights or other securities in
PledPharma AB. An invitation to relevant persons to subscribe for shares in
PledPharma will only be made through the prospectus that PledPharma intends to
publish on its website when such prospectus has been approved and registered by
the Swedish Financial Supervisory Authority (Sw. Finansinspektionen). The
prospectus will contain, among other things, information on risk factors
associated with the company’s business or the securities referred to in this
press release, financial statements as well as information regarding the
company’s board of directors. This press release has not been approved by any
regulatory authority and does not constitute a prospectus. Investors should not
subscribe for or purchase any securities referred to in this press release,
unless such investment decision is based on the information contained in the
prospectus that will be published by PledPharma. 

The information in this press release is not intended to be, and may not be,
announced, published or distributed, directly or indirectly, in the United
States, Canada, Japan, Australia, Hong Kong, New Zeeland, Singapore, South
Africa or any other country where such action would be illegal or is wholly or
partially subject to legal restrictions or where such action would require
additional prospectuses, other offer documentation, registrations or other
actions in addition to what follows from Swedish law. The recipient of this
press release is responsible for that the recipient’s use of this press release
and the information contained herein is in accordance with applicable laws in
any relevant jurisdictions. 

If and to the extent that this press release is communicated in any European
Economic Area (EEA) member state that has implemented Directive 2003/71/EC in
its current wording (together with any applicable implementing measures in such
member state, the "Prospectus Directive"), this press release is only addressed
to and directed at persons in such EEA member state who meet the criteria for
an exemption from the obligation to draw up and publish a prospectus as
implemented in such member state, such as for example qualified investors as
defined in the Prospectus Directive. 

This press release does not, and will not, contain or constitute an invitation
or offer to acquire or subscribe for securities in the United States. The
securities referred to in this press release may not be offered or sold in the
United States without registration or an exemption from registration in
accordance with the United States Securities Act of 1933 in its current wording
(“Securities Act”). PledPharma does not intend to register any securities
referred to herein in the United States or to make a public offering of the
securities in the United States. 

This press release, and any other material concerning the securities referred
to herein, is only being distributed to and directed at (i) persons outside the
United Kingdom and Northern Ireland (ii) persons with professional experience
in matters relating to investments who fall within the scope of Article 19(5)
of the Financial Services and Markets Act 2000 (Financial Promotion) Order
2005, as amended (the "Financial Promotion Order"), or (iii) high net worth
companies and other persons to whom this press release may otherwise be
lawfully communicated pursuant to Article 49(2)(a) to (d) of the Financial
Promotion Order. All persons in (i) – (iii) above are together being referred
to as "relevant persons". The securities referred to in this press release are
only available to relevant persons, and any invitation, offer or agreement
regarding the subscription or acquisition of such securities is directed
exclusively at such relevant persons. A person who is not a relevant person may
not act on or rely upon this press release or the information contained herein.



Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10